Edition:
United States

Array Biopharma Inc (ARRY.OQ)

ARRY.OQ on NASDAQ Stock Exchange Global Market

8.77USD
3:23pm EDT
Change (% chg)

$-0.04 (-0.45%)
Prev Close
$8.81
Open
$8.81
Day's High
$8.84
Day's Low
$8.59
Volume
274,242
Avg. Vol
966,070
52-wk High
$13.38
52-wk Low
$2.70

Latest Key Developments (Source: Significant Developments)

Array enters into loan, security agreement
Friday, 23 Dec 2016 04:24pm EST 

Array Biopharma Inc : Array Biopharma -on December 22, 2016 entered into loan and security agreement providing for term loan in original principal amount of $15 million . Array Biopharma -on December 22, 2016 entered into loan and security agreement providing for revolving line of credit of up to $5 million . Array Biopharma Inc - loan agreement also provides for revolving line of credit of up to $5 million - SEC filing .Array Biopharma -co requested issuance of letter of credit of $2.8 million to secure obligations under lease agreement for Boulder, Colorado facilities.  Full Article

Array Biopharma prices public offering at $6.25 per share
Tuesday, 27 Sep 2016 09:25pm EDT 

Array Biopharma Inc : Array Biopharma announces pricing of public offering of common stock .Says public offering of 18.4 million common shares priced at $6.25 per share.  Full Article

Array Biopharma announces proposed public offering of common stock
Tuesday, 27 Sep 2016 04:27pm EDT 

Array Biopharma Inc : Array Biopharma announces proposed public offering of common stock .Commenced an underwritten public offering of $100 million of shares of its common stock.  Full Article

Array Biopharma enters into note purchase agreement
Friday, 2 Sep 2016 05:15pm EDT 

Array Biopharma Inc : On Sept 2, co entered into note purchase agreement - SEC filing . Notes bear interest at rate of 5 percent per annum . Co issued to Redmile subordinated convertible promissory notes (in aggregate original principal amount of $10 million Source: (http://bit.ly/2c1a5cZ) Further company coverage: [ARRY.O] ((bangalore.newsroom@thomsonreuters.com;)).  Full Article

Array Biopharma announces FDA acceptance of Binimetinib for patients with advanced NRAS-mutant melanoma
Thursday, 1 Sep 2016 08:00am EDT 

Array Biopharma Inc : Announces FDA acceptance Of Binimetinib NDA for patients with advanced NRAS mutant melanoma . Says currently preparing for an application orientation meeting (AOM) with FDA in September 2016 .FDA set target action date under prescription drug user fee act (PDUFA) of June 30, 2017.  Full Article

Array Biopharma files for mixed shelf of up to $300 mln
Thursday, 18 Aug 2016 05:24pm EDT 

Array Biopharma Inc :Files for mixed shelf of up to $300 million - SEC filing.  Full Article

Array Biopharma Q4 net loss $0.17 per share
Thursday, 4 Aug 2016 08:00am EDT 

Array Biopharma Inc : Array Biopharma reports financial results for the fourth quarter and full year of fiscal 2016 . Net loss for Q4 was $0.17 per share . Revenue for Q4 of fiscal 2016 was $43.2 million, compared to $43.0 million for prior sequential quarter .Q4 earnings per share view $-0.14, revenue view $41.5 million -- Thomson Reuters I/B/E/S.  Full Article

Array Biopharma names new CFO
Thursday, 28 Jul 2016 08:00am EDT 

Array Biopharma Inc : Array Biopharma announces appointment of Jason Haddock as chief financial officer .Haddock's appointment effective today and he will be replacing David Horin, who had been acting as Array's interim CFO.  Full Article

Array biopharma submits Binimetinib new drug application to U.S. FDA
Thursday, 30 Jun 2016 04:00pm EDT 

Array Biopharma Inc : Array biopharma submits binimetinib new drug application to u.s. Fda . Binimetinib was generally well-tolerated and adverse events reported were consistent with previous results . There was no statistically significant difference demonstrated in overall survival,median overall survival favored binimetinib arm .Array biopharma submits binimetinib new drug application to u.s. Fda.  Full Article

Merck KGaA partners with Array BioPharma, Pierre Fabre on mCRC phase iii trial
Saturday, 4 Jun 2016 09:23am EDT 

Merck KGaA : Says partners with Array BioPharma and Pierre Fabre to initiate braf-mutant mCRC phase iii trial Further company coverage: [MRCG.DE] ((frankfurt.newsroom@thomsonreuters.com; +496975651270;)).  Full Article

More From Around the Web

BRIEF-Array Biopharma provides NEMO update

* Array Biopharma Inc - Has withdrawn from U.S. FDA division of oncology products 2 its new drug application (NDA) for binimetinib monotherapy